YOLFTbeta
Roche CDR (CAD Hedged)

Roche CDR (CAD Hedged)

ROG · NEO · Healthcare / Drug Manufacturers - General

28.81CAD+2.36 (+8.92%)

Price History

Full chart

Market Stats

Previous Close26.45
Open28.81
Day Range28.81 – 28.81
52-Week Range20.14 – 28.81
Volume200
Market Cap466.16B
P/E (TTM)0.00
Forward P/E16.18
EPS1.02
Dividend Yield2.23%
Beta0.18
50-Day Avg21.30
200-Day Avg21.21

About

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Thomas Schinecker
  • Employees103.25K
  • HeadquartersGrenzacherstrasse 124, Basel, Switzerland, 4070, Canada
  • Websitehttps://www.roche.com

Leadership

  • Dr. Severin Schwan Ph.D.Executive Chairman · b. 1967
  • Dr. Thomas SchineckerGroup Chief Executive Officer · b. 1975
  • Dr. Alan HippeChief Financial Officer · b. 1967
  • Dr. Bruno EschliHead of Investor Relations
  • Ms. Claudia BockstiegelGeneral Counsel · b. 1964
  • Ms. Pascale SchmidtChief Compliance Officer · b. 1973
  • Ms. Barbara SchadlerHead of Group Communications · b. 1962
  • Ms. Maria Cristina A. WilburChief People Officer · b. 1967
  • Dr. Nicolas DunantHead of Group Media Relations
  • Mr. Boris L. ZaitraHead of Corporate Business Development · b. 1972

Financials

Income Statement

Currency: CHF2022-12-312023-12-312024-12-312025-12-31
Total Revenue65.81B60.44B62.40B63.36B
Growth (%)--8.16%+3.23%+1.54%
Cost of Revenue19.74B16.36B16.28B16.64B
Gross Profit46.08B44.08B46.11B46.71B
Gross Margin70.01%72.94%73.90%73.73%
Operating Expense28.60B28.69B32.70B28.23B
Operating Income17.48B15.39B13.42B18.48B
Operating Margin26.55%25.47%21.50%29.16%
Net Income12.42B11.50B8.28B12.88B
Net Income Margin18.87%19.02%13.27%20.33%
R&D15.22B14.20B15.30B13.35B
R&D as % of Total Revenue23.13%23.49%24.53%21.07%
Interest Expense690.00M997.00M1.40B1.35B
Interest Expense % of Total Revenue1.05%1.65%2.25%2.12%

Balance Sheet

Currency: CHF2022-12-312023-12-312024-12-312025-12-31
Total Assets88.15B90.47B101.80B100.70B
Total Liabilities56.14B57.20B65.64B62.82B
Total Equity27.99B29.32B31.77B33.80B
Cash4.99B5.38B6.97B5.58B
Net Debt20.36B23.83B27.68B26.05B

Cash Flow

Currency: CHF2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-17.80B16.09B20.09B18.85B
Capital Expenditure04.55B4.65B5.01B5.78B
Free Cash Flow-13.25B11.45B15.09B13.07B
Dividends Paid-7.45B7.59B7.65B7.73B
FCF to OCF-74.43%71.12%75.07%69.35%
Dividend Paid to FCF-56.19%66.31%50.71%59.14%

Key Statistics & Ratios

Market Cap466.16B
Enterprise Value543.84B
Trailing P/E0.00
Forward P/E16.18
PEG Ratio1.48
Price / Sales7.34
Price / Book8.04
EPS1.02
Book Value36.01
Revenue (TTM)63.49B
Gross Profit (TTM)47.48B
EBITDA23.43B
Profit Margin14.85%
Operating Margin36.14%
Return on Equity31.32%
Return on Assets13.30%
Shares Outstanding13.86B
Shares Float727.61M
Beta0.18
Dividend Yield2.23%
Dividend Rate0.49
Payout Ratio0.00%

Dividends

20261×
0.50Mar 13, 2026
20251×
0.49Mar 27, 2025